Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to standard endoscopic retrograde cholangiopancreatography (ERCP) with brushing cytology for diagnosis and early detection of cholangiocarcinoma in patients diagnosed with primary sclerosing cholangitis (PSC).
The primary objective of this study is to demonstrate the clinical utility of the addition of per oral cholangioscopy (POCS) to standard ERCP with brushing cytology for diagnosis and early detection of cholangiocarcinoma in patients diagnosed with primary sclerosing cholangitis (PSC).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Consented, enrolled PSC patients undergoing ERCP + SpyGlass | Patients with PSC who have been consented and enrolled in the study will undergo ERCP with the addition of SpyGlass as indicated by their treating physician. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SpyGlass DS I - II | Device | The SpyScopeâ„¢ DS Access and Delivery Catheter (SpyScopeâ„¢ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller. |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic Accuracy of POCS visualization for Early Detection of Cholangiocarcinoma | Diagnostic accuracy of POCS visualization for cholangiocarcinoma evaluated clinically at 12 months after initial POCS procedure by clinical presentation. | 12 months |
| POCS-guided Biopsy for Early Detection of Cholangiocarcinoma | Diagnostic accuracy for POCS-guided Biopsy for cholangiocarcinoma evaluated on pathology at 12 months after initial POCS procedure. | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Technical Success - Ability to advance the scope. | Ability to advance the cholangioscope to the target stricture, ability to visualize the stricture and ability to obtain a tissue sample with Spy Bite where applicable. | Baseline |
| Rate of Adverse Events |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients diagnosed with PSC
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Johannes Eksteen, MD, PhD | Aspen Woods Clinic | Principal Investigator |
| Douglas Adler, MD | University of Utah Hospital and Clinic | Principal Investigator |
| Lars Aabakken, MD, PhD | Rikshospitalet Oslo University Hospital | Principal Investigator |
| Cyriel Ponsioen, MD, PhD | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Principal Investigator |
| Sooraj Tejaswi, MD, PhD | Sutter Davis Hospital | Principal Investigator |
| Christopher Bowlus, MD, PhD | UC Davis Health | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sutter Davis Hospital | Davis | California | 95616 | United States | ||
| UC Davis Health |
| ID | Term |
|---|---|
| D015209 | Cholangitis, Sclerosing |
| D018281 | Cholangiocarcinoma |
| ID | Term |
|---|---|
| D002761 | Cholangitis |
| D001649 | Bile Duct Diseases |
| D001660 | Biliary Tract Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Serum collection
|
Serious adverse events from initial POCS procedure until end of follow-up. |
| From index through study completion, an average of one year |
| Proportion of patients identified for repeat procedure. | Proportion of patients identified for repeat procedure considering the addition of Spy Glass DS visualization and Spy Bite biopsy at Index compared to the proportion identified for repeat procedure without consideration of Spy Glass DS visualization and Spy Bite biopsy at Index. | During index procedure |
| Correspondence of Biopsies | Correlation between histopathology of Spy Bite biopsies collected during the initial POCS procedure and final diagnosis. | From index through study completion, an average of one year |
| Sacramento |
| California |
| 95817 |
| United States |
| University of Utah Hospital and Clinic | Salt Lake City | Utah | 84132 | United States |
| Aspen Woods Clinic | Calgary | Alberta | T3H 0V5 | Canada |
| Academic Medical Center | Amsterdam-Zuidoost | 1105 AZ | Netherlands |
| Rikshospitalet University Hospital | Oslo | 0372 | Norway |
| D000230 |
| Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |